Barclays Raises Colgate (CL) Target to $83 but Stays Cautious on Fundamentals

Colgate-Palmolive Company (NYSE:CL) is included among the 13 Best Dividend Kings to Buy in 2026.

On January 16, Barclays analyst Lauren Lieberman raised Barclays’ price target on Colgate-Palmolive Company (NYSE:CL) to $83 from $80 and kept an Equal Weight rating on the stock. The change came as part of the firm’s broader Q4 earnings preview for the consumer staples group, where it updated several targets across the sector. Barclays said the recent “enthusiasm” around Colgate’s shares appears to be driven largely by “a flight to safety,” as investors rotate into more defensive names. Even so, the firm said it is still uneasy about the company’s fundamentals, as well as the overall backdrop for the sector. The analyst also flagged potential pressures in 2026, warning that oil and currency headwinds could become more meaningful.

Just a few days earlier, on January 13, Wells Fargo took a more constructive turn on the stock. The firm upgraded Colgate to Equal Weight from Underweight and raised its price target to $86 from $77. Wells Fargo said the stock now offers a more balanced risk/reward profile at current levels, adding that many of the key concerns around sales growth and valuation have already played out.

Colgate-Palmolive Company (NYSE:CL) is a consumer products company focused on categories such as Oral Care, Personal Care, Home Care, and Pet Nutrition.

While we acknowledge the potential of CL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Growth Stocks with the Highest Growth Rates and 14 Best Mid Cap Dividend Aristocrat Stocks to Buy Now

Disclosure: None.